Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids

Tomonori Moritaka, Katsuyuki Kiura, Hiroshi Ueoka, Masahiro Tabata, Yoshihiko Segawa, Takuo Shibayama, Nagio Takigawa, Taisuke Ohnoshi, Mine Harada

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)


A cisplatin-resistant cell line, SBC-3/CDDP, was established from a human small-cell lung cancer cell line, SBC-3. The SBC-3/CDDP cells were 13.1-fold more resistant to cisplatin than the parent SBC-3 cells. We investigated the cellular changes of this cell line with regard to the development of resistance to cisplatin. The SBC-3/CDDP cells showed various characteristics as follows: a) increased intracellular glutathione and glutathione S-transferase content b) decreased intracellular accumulation of cisplatin, c) increased topoisomerase I activity and the same topoisomerase II activity as the patent SBC-3 cells, and 4) strong cross-resistance to the platinum analogies and mitomycin C, moderate cross-resistance to 7-ethyl-10-hydroxy-camptothecin (SN-38), 4-hydroperoxy cyclophosphamide, etoposide, Adriamycin and methotrexate, and collateral sensitivity to vinca alkaloids and 5-fluorouracil. From these observations, the SBC-3/CDDP cells could be useful as a well characterized cisplatin-resistant cell line, and the resistance pattern in this cell line will give us much information for eradication of cisplatin-resistant tumor cells.

Original languageEnglish
Pages (from-to)927-933
Number of pages7
JournalAnticancer research
Issue number2 A
Publication statusPublished - Mar 1 1998


  • 5-fluorouracil
  • Cisplatin
  • Glutathione
  • Glutathione S-transferase
  • Small-cell lung cancer
  • Topoisomerase I and II
  • Vinca alkaloids
  • Π

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids'. Together they form a unique fingerprint.

Cite this